ST Pharm Co.,Ltd. (KOSDAQ:237690)
South Korea
· Delayed Price · Currency is KRW 160,000
+11,200 (7.53%)
At close: Mar 6, 2026
ST Pharm Revenue
ST Pharm had revenue of 81.91B KRW in the quarter ending September 30, 2025, with 32.75% growth. This brings the company's revenue in the last twelve months to 318.32B, up 14.24% year-over-year. In the year 2024, ST Pharm had annual revenue of 273.75B, down -3.94%.
Revenue (ttm)
318.32B
Revenue Growth
+14.24%
P/S Ratio
10.44
Revenue / Employee
485.98M
Employees
655
Market Cap
3,324.27B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 273.75B | -11.24B | -3.94% |
| Dec 31, 2023 | 284.99B | 35.67B | 14.31% |
| Dec 31, 2022 | 249.32B | 83.68B | 50.52% |
| Dec 31, 2021 | 165.64B | 41.53B | 33.47% |
| Dec 31, 2020 | 124.11B | 30.85B | 33.08% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,556.97B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| Sam Chun Dang Pharm. | 220.74B |
| Mezzion Pharma | 7.75B |
| D&D Pharmatech | 8.36B |
| CLASSYS | 336.80B |
| PharmaResearch | 496.03B |